Date: 2012-01-24
Type of information: Licensing agreement
Compound: fipamezole
Company: Ipsen (France) Santhera Pharmaceuticals (Switzerland)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: licensing (renegociation of an agreement)
Action mechanism: Fipamezole is a highly selective adrenergic alpha-2 receptor antagonist.
Disease: levodopa-induced dyskinesia in Parkinson's Disease>
Details: According to a licensing agreement signed in September 2010, Ipsen had acquired the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of €13 million. Under the new agreement, Santhera regains full control over the development and commercialization of fipamezole, whilst Ipsen is entitled to receive milestone and royalty payments contingent upon the occurrence of certain events. Santhera is free to license the program to a third party whereby Ipsen is entitled to receive a percentage of any license income. In addition, the agreement includes a call option allowing Ipsen under certain circumstances to obtain an exclusive worldwide license. Should Ipsen exercise this call option, Santhera will receive milestone and royalty payments from Ipsen.
Financial terms:
Latest news:
